INTRODUCTION
The 'critically important' aminoglycoside amikacin is successfully used for the treatment of severe systemic infections caused by susceptible Gram-negative bacteria and as a second-line antibiotic in combatting multidrug-resistant tuberculosis (Durante-Mangoni et al., 2009; WHO, 2011 WHO, , 2012 . Therefore, the effective in vitro activity of amikacin is of vital interest for patients and for public health, and treatment options for this antimicrobial should be retained as long as possible. Amikacin is rendered ineffective by target site mutations or methylation, reduced uptake or increased excretion and by the action of horizontally transferred genes coding for aminoglycoside-modifiying enzymes that acetylate, adenylate or phosphorylate the agent (Magnet & Blanchard, 2005; Wright & Thompson, 1999; Yuan et al., 2013) . APH(39)-IIIa (synonym: NPTIII) appears to be the most prevalent aminoglycoside phosphotransferase in Gram-positive bacteria and gains clinical relevance by the fact that it shows the broadest substrateinactivation spectrum of these protein family members (Becker & Cooper, 2013; Fong & Berghuis, 2002) . Besides amikacin, various other aminoglycosides like neomycin, kanamycin -both recently also classified as 'critically important' antimicrobials by a World Health Organization working group (WHO, 2012) -and paromomycin, ribostamycin, lividomycin, butirosin, gentamicin B and isepamicin are inactivated by APH(39)-IIIa (Shaw et al., 1993) . A similar antimicrobial inactivation profile except for amikacin, lividomycin and isepamicin is displayed by APH(39)-IIa (NPTII) (Ramirez & Tolmasky, 2010) . Both phosphotransferase genes are present in synthetic vectors and in naturally occurring mobile genetic elements on plasmids and in transposons, and thus are supposed to be horizontally transferable between bacterial pathogens (Beck et al., 1982; Trieu-Cuot & Courvalin, 1983; Wright & Thompson, 1999) .
In Austria, phenotypic resistance to aminoglycoside antibiotics (amikacin, gentamicin and tobramycin) is routinely monitored for the bacterial species analysed in the present study (Apfalter et al., 2012) : aminoglycoside resistance has been reported to be low for Salmonella (kanamycin) and Escherichia coli resulting in 0.6 and 6.3 % resistant strains in 2011 (Apfalter et al., 2012) . Of the noninvasive clinical Staphylococcus aureus isolates, 4.5 % were resistant to gentamicin, as were 11.2 % of the invasive isolates of Pseudomonas aeruginosa; in contrast, 30.4 and 49.8 % of Enterococcus faecalis and Enterococcus faecium isolates, respectively, showed high-level resistance to aminoglycosides in the same year. Except for Salmonella, increased resistance to aminoglycoside antibiotics was observed for all these reference strains over the last 4-5 years (Apfalter et al., 2012) . Information about the causative genotype is not available for Austria. To our knowledge, the prevalence of aminoglycoside phosphotransferase genes is also only minimally monitored for the rest of Europe. However, in combatting the spread of antibiotic resistance, monitoring of phenotypic resistance rates is essential and the availability of information about the epidemiology of the genetic elements responsible for the expressed phenotype is crucial (Schmieder & Edwards, 2012) . To obtain an overview of the role of aph(39)-IIIa and aph(39)-IIa genes in aminoglycoside resistance in Austria, six major bacterial species responsible for a substantial burden of disease locally (Apfalter et al., 2012) and worldwide (ECDC, 2012) were sampled representatively, avoiding selection bias. Sampling, PCR validation and statistical analysis were designed to provide prevalence data of high confidence.
aph(39)-IIIa was selected for prevalence analysis due to its reported status as an abundant aminoglycoside phosphotransferase gene in clinical settings with the broadest substrate-inactivation spectrum including amikacin (Becker & Cooper, 2013) and aph(39)-IIa was chosen as a comparator. Both genes are the most frequently applied antibiotic resistance marker genes in gene technology and therefore also of relevance for the risk assessment of transgenic organisms (Rosellini, 2012; Wright & Thompson, 1999) .
METHODS
Sampling plan. To achieve a precision of ±1 % and a statistical power of 50 %, at least 384 bacterial isolates per species had to be collected and analysed. At least one clinical microbiology laboratory representatively selected from each of the nine provinces of Austria took part in the survey. Usually, the one with the highest sample turnover rate in the respective province was chosen. The requested sample number per province was adjusted relative to the total number of inhabitants.
Bacterial strains. In total, 10 541 initial isolates (444 Escherichia coli; 437 Enterococcus faecalis and Enterococcus faecium; 986 Pseudomonas aeruginosa; 439 Staphylococcus aureus; 8235 Salmonella enterica subsp. enterica) were collected consecutively, identified on site at the participating clinical microbiological laboratories using the locally established and validated routine procedures and sent to the study collection centre in Graz (AGES -Institute for Medical Microbiology and Hygiene, Graz, Austria; for the collaborating peripheral laboratories see Table S1 , available in JMM Online). Isolates were stored at 280 uC in cryobank vials (Mast Diagnostics) until further analysis. The collected strains were obtained from the following specimen types: urine, wound infections, blood, faeces, stomach secretions, tracheal secretions, cervical secretions, bile, breast milk, sperm, amniotic fluid, and skin swabs and throat swabs. Escherichia coli isolates were sampled from February to July 2011, and species identification was confirmed on MacConkey agar (Becton Dickinson) and using CPS3 Chromogenagar (bioMérieux), an indol test (James reagent; Biomedica) and VITEK 2 (bioMérieux) or API 20 E (bioMérieux). Enterococcus faecalis and Enterococcus faecium isolates were sampled from February to July 2011, and species identification was performed using agar selective for enterococci (no. 45183; SigmaAldrich) and was biochemically confirmed by VITEK 2 (bioMérieux). P. aeruginosa was collected from July to November 2010, recultivated on MacConkey and Columbia blood agar plates (Becton Dickinson) and biochemically identified using an oxidase test (Sigma-Aldrich) and VITEK 2 or API 20 NE strips (bioMérieux). Staphylococcus aureus was sampled from February to July 2011, and species identification was confirmed on Columbia blood agar plates (Becton Dickinson), by catalase reaction, by testing for clumping factor and protein A (e.g. Staphyloslide; Becton Dickinson) and by VITEK 2 or RapiDEC (bioMérieux). Salmonella samples were obtained from the strain collection of the Austrian Reference Centre for Salmonella (AGES, Graz). All isolates were serotyped and biochemically characterized according to the White-Kauffmann-Le Minor scheme (Health Protection Agency, 2007 DNA isolation. Isolates were inoculated directly from the cryobank vials into 100 ml brain-heart infusion broth (Oxoid) and incubated overnight at 37 uC in an ambient atmosphere. After centrifugation, the pellet was resuspended in 100 ml QuickExtract DNA Extraction Solution 1.0 (Epicentre) and incubated at 65 uC for 7 min and at 98 uC for 5 min. A 1 : 10 dilution in molecular biology-grade water (Sigma-Aldrich) was used as template for all TaqMan PCR assays.
Screening of aph(3 §)-IIIa and aph(3 §)-IIa resistance genes. Tests for aph(39)-IIIa and aph(39)-IIa gene targets were performed simultaneously in a single well on a LightCycler 480 real-time PCR platform (Roche) using 96-well microtitre plates. PCR TaqMan double assays were prepared according to the recommendations of the manufacturer (Ingenetix). In brief, the amplification mix contained 5 ml 26 LC480 Probes Master (Roche), 0.5 ml nptIII mix (0.6 mM primer each, 0.2 mM 59YYE-labelled probe) and 0.5 ml nptII mix (0.6 mM primer each, 0.2 mM FAM-labelled probe) and 2 ml molecular biology-grade water (Sigma). Two microlitres of template was added resulting in a total PCR assay volume of 10 ml. The PCR conditions were as follows: initial denaturation at 95 uC for 10 min, followed by 45 cycles of denaturation at 95 uC for 10 s and annealing and elongation at 60 uC for 20 s. For primer and probe sequences and amplicon size, see Table 1 .
Amplification and DNA extraction control: 16S rRNA TaqMan single screening assay. Each sample was tested for amplifiable DNA and for PCR inhibition by analysing 2 ml of the 1 : 10 dilution of the same QuickExtract (Epicentre) template as used for the double assays with a control 16S rRNA TaqMan assay. The PCR assay contained 5 ml 26 LC480 Probes Master (Roche), 0.28 ml degenerated primer mix (final concentration: 0.5 mM each; Ingenetix) and 0.5 ml Cy5-labelled probe at a final assay concentration of 0.2 mM, made up to a total of 10 ml with molecular biology-grade water. The PCR conditions were as follows: initial denaturation at 95 uC for 10 min, followed by 45 cycles of denaturation at 95 uC for 10 s and annealing and elongation at 60 uC for 1 min. The cut-off threshold for a positive 16S rRNA TaqMan assay was set at a crossing point of 27. Samples with a negative 16S TaqMan assay result (crossing point .27) were excluded from statistical analysis if the aph(39)-IIIa and/or aph(39)-IIa PCR results were negative to avoid false-negative results.
PCR assay validation. The 95 % detection limit for aph(39)-IIIa was 11.4 and for aph(39)-IIa was 7.9 copies per assay (median). 
RESULTS

Prevalence of aph(3 §)-IIIa
Of 10 440 validly tested isolates, 1.62 % harboured the aph(39)-IIIa aminoglycoside phosphotransferase gene (Table 2) . From a total of 444 Escherichia coli isolates initially collected, 428 samples produced PCR results eligible for evaluation (11 isolates could not be recultivated and five were excluded from statistical analysis due to a negative 16S amplification and a negative aph(39)-IIIa PCR result), leading to an aph(39)-IIIa prevalence of 0.47 % in this species during the test period.
Of 413 enterococci isolates, 37.53 % were aph(39)-IIIa positive (from a total of 437 collected samples excluding 10 drop-outs and 14 negative amplification controls).
Of 413 Staphylococcus aureus isolates, 2.9 % were carriers of aph(39)-IIIa (total: 439 samples; excluding six drop-outs and 20 negative amplification controls). No aph(39)-IIIapositive isolates could be retrieved from 951 P. aeruginosa (total: 986 samples; excluding two drop-outs and 33 negative amplification controls) and from 8235 Salmonella enterica subsp. enterica samples.
The upper limit of the 95% confidence interval (CI) for aph(39)-IIIa resistance genes in all tested human pathogenic bacteria was 1.88 % (two-sided CI). For Escherichia coli, enterococci, Staphylococcus aureus, P. aeruginosa and Salmonella isolates, the upper limits of the 95 % CIs were 1.47 % (one-sided), 42.40 % (two-sided), 5.02 % (two-sided), 0.32 % (one-sided) and 0.037 % (one-sided), respectively (Fig. S1 ).
Prevalence of aph(3 §)-IIa
Of 10 429 validly tested isolates, 0.0096 % harboured the aph(39)-IIa aminoglycoside phosphotransferase gene ( This resulted in a prevalence for aph(39)-IIa in this species of 0.013 %. All other tested species were negative for aph(39)-IIa.
The upper limit of the one-sided 95 % CI for aph(39)-IIa resistance genes in all tested human pathogenic bacteria was 0.046 %. For Escherichia coli, enterococci, Staphylococcus aureus, P. aeruginosa and Salmonella isolates, the upper limits of the one-sided 95 % CIs were 0.70, 0.75, 0.73, 0.32 and 0.058 %, respectively (Fig. S2) .
Sequencing of aph(3 §)-IIIa/IIa-positive strains
Ten of 155 enterococcal, one of 12 staphylococcal and none of the two Escherichia coli strains of a total of 169 aph(39)-IIIa carriers showed single-nucleotide polymorphisms in the resistance gene, as listed in Table 4 . There were two silent mutations at positions 564 and 597 in Enterococcus EK_360 and Staphylococcus aureus ST_405, respectively. All other mutations led to an exchange of an amino acid in the aminoglycoside phosphotransferase enzyme. However, all (Brown et al., 2001) . §Enterococcus faecalis and Enterococcus faecium isolates combined. # In total, 8235 samples were tested for resistance to kanamycin (disk diffusion test: inhibition diameter: ¡13 mm; according to CLSI clinical breakpoints). Sixty isolates appeared to be resistant and were analysed by TaqMan real-time PCR. If the PCR results of only these 60 isolates were analysed statistically, the corresponding results were: none of the strains was aph(39)-IIIa positive resulting in a prevalence estimator of 0 % and a 95 % CI of 0-4.88 % for these 60 samples. Using this approach, non-expressed aph(39)-IIIa genes and gene variants producing no active enzyme were not detectable. nptIII/nptII in human bacterial pathogens in Austria of these strains showed high-level resistance to kanamycin (see below). The aph(39)-IIa-positive Salmonella strain showed complete sequence identity to the aph(39)-IIa reference sequence of Tn5 (GenBank accession no. V00618).
MIC determination of aph(3 §)-IIIa/IIa-positive strains
MICs of kanamycin were determined for all aph(39)-IIIaand aph(39)-IIa-positive strains using an Etest. 
DISCUSSION
In the present study, we analysed the abundance of the aminoglycoside phosphotransferase genes aph(39)-IIIa and aph(39)-IIa in a comprehensive collection of bacterial human pathogens in Austria. Both enzymes inactivate a broad spectrum of aminoglycoside antibiotics including the critically important antimicrobials kanamycin, neomycin and amikacin, although the latter is not modified by APH(39)-IIa to a clinically relevant extent (Shaw et al., 1993; WHO, 2012) . The overall prevalence of aph(39)-IIIa (1.62 %) and aph(39)-IIa (0.0096 %) was low in the gene pool of the bacterial species tested. Only enterococci proved to be a significant reservoir for aph(39)-IIIa (37.53 %). These results are in accordance with phenotypic resistance monitoring data routinely obtained for the European Antimicrobial Resistance Surveillance Network, which report a low to moderate incidence of phenotypic aminoglycoside resistance in Austria except for Enterococcus faecalis and Enterococcus faecium (ECDC, 2012). These two species gave high-level resistance rates of 30.4 and 49.8 %, respectively, in 2011 (Apfalter et al., 2012) . According to Apfalter et al. (2012) , a statistically significant increase in aminoglycoside resistance over the past 4 years was noted; the incidence of high-level aminoglycoside resistance of invasive Enterococcus faecalis and Enterococcus faecium isolates started from a baseline of 20.9 and 20.7 %, respectively, in 2008, indicating an aggravation of the resistance status (Apfalter et al., 2012; ECDC, 2012) . Although referring to phenotypic high-level aminoglycoside resistance rates retrieved from the national monitoring programme only provides indirect evidence, the relatively high prevalence of the gene in the total population and the high rate of WT sequences in the positive enterococcal isolates are indicative of a relevant role of aph (39) Aminoglycoside non-sensitive invasive P. aeruginosa isolates increased from 8 to 11.2 % from 2008 to 2011 in Austria (Apfalter et al., 2012) . In our samples collected representatively in Austria in 2010, aph(39)-IIIa and aph(39)-IIa genes appeared not to be involved in aminoglycoside resistance. Amikacin resistance of P. aeruginosa was reported to be frequent in Korea (22 %) in 2002, but aph(39)-IIIa or aph(39)-IIa was also not detected (Kim et al., 2008) . In France, 23 % of the isolated Pseudomonas strains were resistant to at least one of four tested aminoglycosides including amikacin in 2008 (Dubois et al., 2008) . The presence of aminoglycoside phosphotransferase genes was not analysed in these resistant strains.
In Austria, aminoglycoside resistance in Escherichia coli was low but rose from 4.3 % in 2009 to 6.3 % in 2011 (Apfalter et al., 2012) . According to our results, aph(39)-IIa was not involved in phenotypic resistance during the test period; however, aph(39)-IIIa was detected in 0.47 % of the isolates collected for the present study.
Salmonella strains showed the lowest resistance rates of all the tested species in Austria, being constantly ¡1 and 0.6 % on average during the period of 2000-2010 (Table  S2 ). This situation was also reflected in the calculated 95 % CIs for the prevalence of aph(39)-IIIa (,0.037 %) and aph(39)-IIa (,0.058 %) in our investigation. Only a single Salmonella isolate could be identified as harbouring aph(39)-IIa. Due to privacy restrictions, there is no information available about the familiar background of the afflicted patient and therefore it is unclear whether this single incidence was due to a local reservoir of an aph(39)-IIa-carrying Salmonella population in Austria or whether this isolate was imported from abroad.
Of the non-invasive clinical Staphylococcus aureus isolates, 4.5 % were resistant to gentamicin in 2011 in Austria (Apfalter et al., 2012) ; aminoglycoside resistance is not monitored for the European Antimicrobial Resistance Surveillance Network for invasive Staphylococcus aureus strains (Apfalter et al., 2012; ECDC, 2012) . Schmitz et al. (1999) reported a prevalence of 7.8 % for aph(39)-IIIa genes in aminoglycoside-resistant Staphylococcus aureus strains as part of the SENTRY study. We showed a prevalence of 2.9 % for this resistance determinant in this pathogen species. However, our data are not directly comparable with the SENTRY results because our samples were collected without aminoglycoside selection, mirroring the abundance of aph(39)-IIIa genes in the gene pool of the observed species not biased by antibiotic pre-selection.
Gram-positive pathogens (i.e. enterococci and to a lesser extent Staphylococcus aureus) appeared to be the major reservoir of the aminoglycoside phosphotransferase genes tested for in our study.
Selection pressure mediated by usage of aminoglycoside antibiotics is limited in Austria: in 2010, 240 kg aminoglycosides were distributed for veterinary applications (Fuchs, 2012) . The human therapeutic application of aminoglycosides was below 1 % of the total consumption of antimicrobials during the same period (Apfalter et al., 2012) .
Our study revealed a striking discrepancy in the gene frequency between aph(39)-IIIa and aph(39)-IIa, the latter being virtually undetectable in more than 10 400 samples, although both genes are supposed to be exposed to a similar selection pressure. Both genes are exactly the same length (795 bp) but do not show high similarity at the nucleotide level (overall identity: 47.3 %, but no extended regions of complete DNA sequence identity; data not shown). According to Shaw et al. (1993) , the amino acid similarity between APH(39)-IIIa and APH(39)-IIa is 52.2 %. aph(39)-IIIa was initially detected on a conjugative plasmid and is found on mobile episomal elements (Derbise et al., 1997; Gibreel et al., 2004; Trieu-Cuot & Courvalin, 1983) . In contrast, aph(39)-IIa was originally identified as a component of transposon Tn5 (Beck et al., 1982) . Tn5 does not carry transfer functions, is essentially non-conjugative and thus follows a vertical inheritance pattern, which may be a plausible explanation for this discrepant dissemination pattern. In general, aminoglycoside-modifying genes are considered to have potential to spread by horizontal gene transfer (Thomas & Nielsen, 2005 (Becker & Cooper, 2013) . AAC(69)-containing proteins are considered the clinically most relevant of all aminoglycoside-inactivating enzymes (Ramirez & Tolmasky, 2010) . We focused our prevalence analysis on aph(39)-IIIa because of its broad distribution and substrate-inactivation spectrum and its role as an antibiotic resistance marker gene in gene technology (Rosellini, 2012; Wright & Thompson, 1999) . In Austria, amikacin is reserved mainly for the treatment of severe systemic infections caused by pathogens that are resistant to other aminoglycosides (Ö GACH, 2012) . Usually, it is applied in combination with b-lactams or glycopeptides (Leibovici et al., 2009) . In staphylococci and enterococci, high-level resistance to kanamycin caused by the production of the aminoglycoside phosphotransferases APH(39)-I-III implies loss of synergism of kanamycin and amikacin with b-lactams and glycopeptides, irrespective of MIC values (Leclercq et al., 2013) .
With the exception of a single Staphylococcus aureus and both Escherichia coli isolates, MIC analysis of the aph(39)-IIIa-positive strains revealed kanamycin-resistant phenotypes. Inhibition of gene expression due to a promoter mutation or sequence aberrations in the untranslated 59 and/or 39 regions of the corresponding mRNAs would be possible explanations for the aberrant results (Kozak, 2005; Picard et al., 2009) . Nine resistant Enterococcus isolates showed single-nucleotide polymorphisms in the aph(39)-IIIa gene that resulted in an exchange of the amino acid at the respective position. However, all of these strains were phenotypically high-level resistant, indicating a mutationtolerant APH(39)-IIIa enzyme or other aminoglycoside resistance mechanism active in the affected strains (Shaw et al., 1993) .
The few available studies on this topic have already indicated that clinical isolates are only infrequently carriers for aph(39)-IIa. An American study showed two decades ago that 2.5 % of the kanamycin-resistant bacterial isolates tested were aph(39)-IIa positive, being predominantly present in Gram-negative bacteria and especially in P. aeruginosa (Shaw et al., 1993) . This is in contrast to our findings where we could show that P. aeruginosa is not a carrier for this resistance gene in Austria. Peirano et al. (2006) could not detect aph(39)-IIa carriers in a small collection of neomycin-resistant Salmonella enterica samples from Brazil. This observation is in accordance with our results. Our findings of a low aph(39)-IIa prevalence are also in accordance with observations of a similar rare incidence in environmental isolates and in total soil DNA preparations (Ma et al., 2011) . The only other available references that provide aph(39)-IIa prevalence information were also obtained from environmental samples that showed a low (Leff et al., 1993; Smalla et al., 1993) or a seasonally fluctuating (Zhu, 2007) prevalence of aph(39)-IIa genes in these habitats.
Although the main aminoglycoside substrates for APH (39)-IIa are kanamycin and neomycin, this phosphotransferase is also capable of inactivating amikacin in vitro, albeit at a slow turnover rate. Clinically relevant aph(39)-IIamediated amikacin resistance has been reported for an Escherichia coli mutant strain that showed a generally reduced aminoglycoside uptake combined with a resistance gene amplification due to an increased copy number of the aph(39)-IIa-containing plasmid (Perlin & Lerner, 1986 ).
In conclusion, we have described a prevalence analysis of two aminoglycoside phosphotransferase genes in a comprehensive pool of clinically important pathogens collected representatively in Austria without selection bias. aph(39)-IIa was virtually not present and, thus, is considered clinically irrelevant. aph(39)-IIIa genes were moderately more prevalent during the test period except for in enterococci, which proved to be a significant reservoir for this resistance determinant. As phenotypic aminoglycoside resistance rates are increasing, the aph(39)-IIIa gene is expected to play a relevant role in aminoglycoside-resistant Enterococcus faecalis-and Enterococcus faecium-mediated infections in Austria.
